Deans' stroke musings: NIH Alzheimer's Initiative to Fund Small Business Biomarker Studies

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, March 10, 2012

NIH Alzheimer's Initiative to Fund Small Business Biomarker Studies

Who is pushing the NIH to do the same for stroke? ASA or NSA I'm looking at you.
http://www.genomeweb.com/nih-alzheimers-initiative-fund-small-business-biomarker-studies
As part of a plan to inject $50 million into Alzheimer's disease studies announced last month, the National Institutes of Health will fund new research by small businesses that seek to discover disease and drug-related biomarkers.

NIH plans to use funding from a number of its institutes through its Small Business Innovation Research and Technology Transfer grants to support a wide range of research at small businesses, including biomarker studies.

These grants were funded under the National Alzheimer's Project Act, which provides a total of $50 million this year and $80 million in 2013 through the Department of Health and Human Services for new research and other initiatives.

"We are getting a far better handle on the molecular basis of Alzheimer's disease, providing real hope for developing entirely new and targeted approaches to treatment and prevention," NIH Director Francis Collins said when he and HHS Secretary Kathleen Sebelius announced the Alzheimer's initiative last month.

"In another remarkable advance, recent applications of the genome-wide association study approach have been important in defining pathways involved in Alzheimer's susceptibility, including prominent roles for lipid metabolism and inflammation. These unexpected results provide the potential of completely new approaches to therapy," Collins said.

The National Human Genome Research Institute plans to fund small business research to discover biomarkers for drug efficacy and safety and to identify and develop personalized treatments for mild cognitive impairment and Alzheimer's disease.

The National Institute of Aging will support studies to identify and develop novel biomarkers for early diagnosis of Alzheimer's and amnestic mild cognitive impairment, including neuroimaging biomarkers and biofluid markers found in blood or cerebrospinal fluid.

The National Institute of Environmental Health Sciences will fund research into biomarkers of early Alzheimer's disease onset and exposure in the brain from banked samples from autopsies.

NIH said in two new funding announcements that it will provide up to $2 million this year for each of these SBIR and the STTR grants.